<DOC>
	<DOCNO>NCT02513784</DOCNO>
	<brief_summary>This randomize , open-label pilot study ass whether treatment chlorhexidine mouthwash alter esophageal gastric cardia microbiome</brief_summary>
	<brief_title>Trial Assess Effects Antimicrobial Mouthwash Esophageal Microbiome</brief_title>
	<detailed_description>Patients schedule upper endoscopy clinical indication randomize 3 week either treatment use twice daily chlorhexidine mouthwash lead endoscopy . There 2-3 study visit , Day 0 Day 21 , subject mouthwash arm , final visit 1-2 week follow Day 21 visit . Subjects require fast overnight prior visit Days 0 21 .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Esophagitis , Peptic</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>Age &gt; 18 Scheduled upper endoscopy clinical indication No allergy contraindication chlorhexidine Use proton pump inhibitor H2 receptor antagonist within 1 month enrollment . Acid suppressant medication raise gastric pH dramatically alter gastric esophageal microbiome . History upper gastrointestinal cancer History histologically prove Barrett 's esophagus History antireflux bariatric surgery , gastric esophageal surgery Use antimicrobial mouthwash within 1 month enrollment Use antibiotic immunosuppressant medication within 3 month enrollment Use steroid inhaler nasal spray within 1 month enrollment HIV immunosuppressed state condition ( e.g . active malignancy ) Pregnant breast feed Inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Microbiome</keyword>
	<keyword>Esophagus</keyword>
	<keyword>Endoscopy</keyword>
	<keyword>Mouthwash</keyword>
</DOC>